Adenovirus OBP-301 significantly decreased the percentage of CD133+ stem-like cells compared to cisplatin or radiation by day 3 after treatment (p < 0.05) w/corresponding suppression of CD133 mRNA at 24 h (p < 0.05) and reduction in CD33 expression OBP-301 significantly alters quiescent cancer stem-like cell states, mobilizing them to have less percent in G0–G1 phase and increased proportion in S-phase, with the killing of cancer-like stem-cells in S-phase OBP-301 mobilizes infected quiescent CD133+ cells in tumor spheres, eradicating dormant cells not reached by other treatments. The gene discussed is CD33; the disease is cancer.